Mirtazapine -SIL NDSRI
References
FAQ's
References
- Van der Burg, Willem J., Tetracyclic compounds, GB1543171A. March 28, 1979, AKZO N. V., Netherlands
- Maris, F. A.; Dingler, E.; Niehues, S., High-performance liquid chromatographic assay with fluorescence detection for the routine monitoring of the antidepressant mirtazapine and its demethyl metabolite in human plasma, Journal of Chromatography B: Biomedical Sciences and Applications, Volume: 721, Issue: 2, Pages: 309-316, 1999 DOI: (10.1016/s0378-4347(98)00460-5)
Frequently Asked Questions
How do we separate Mirtazapine impurities from the drug product?
High-performance thin layer chromatography (HPTLC) is the analytical method to separate Mirtazapine impurities from the drug product.
What are the reasons for conducting impurity profiling of Mirtazapine impurities?
Regulatory requirements and maintaining drug quality are the reasons for conducting impurity profiling of Mirtazapine impurities.
What are the conditions under which Mirtazapine undergoes degradation?
Mirtazapine degrades under alkaline, acidic, photolytic, and oxidative conditions.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.